Results 181 to 190 of about 1,923,383 (256)

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Blood, 2017
K. Hay, L. Hanafi, Daniel H. Li, Juliane Gust, W. Liles, M. Wurfel, José A. López, Jun-Mei Chen, D. Chung, Susanna Harju-Baker, S. Cherian, Xue-Yan Chen, S. Riddell, D. Maloney, C. Turtle   +14 more
semanticscholar   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Toxicities of chimeric antigen receptor T cells: recognition and management.

Blood, 2016
Jennifer N. Brudno, J. Kochenderfer
semanticscholar   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

Arthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen, Sanjaykumar Boddul, Zhaojun Li, Zsolt Kasza, Marlene Schülein, Bruno Raposo, Karine Chemin, Per‐Johan Jakobsson, Alexander Espinosa, Lars Klareskog, Fredrik Wermeling   +10 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Journal of Clinical Oncology, 2015
J. Kochenderfer, M. Dudley, Sadik H. Kassim, R. Somerville, R. O. Carpenter, M. Stetler-Stevenson, J. Yang, G. Phan, M. Hughes, R. Sherry, M. Raffeld, Steven R. Feldman, Lily Lu, Yong F Li, L. Ngo, A. Goy, T. Feldman, D. Spaner, Michael L. Wang, Clara C. Chen, S. Kranick, A. Nath, Debbie-Ann N. Nathan, K. Morton, M. A. Toomey, S. Rosenberg   +25 more
semanticscholar   +1 more source